Sustained delivery of GDNF: towards a treatment for Parkinson's disease
Détails
ID Serval
serval:BIB_B9B87CE64673
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Sustained delivery of GDNF: towards a treatment for Parkinson's disease
Périodique
Brain Research. Brain Research Reviews
ISSN
0165-0173 (Print)
Statut éditorial
Publié
Date de publication
10/2001
Volume
36
Numéro
2-3
Pages
222-9
Notes
Journal Article
Research Support, Non-U.S. Gov't
Review --- Old month value: Oct
Research Support, Non-U.S. Gov't
Review --- Old month value: Oct
Résumé
Parkinson's disease (PD) is a neurodegenerative disease characterized by the progressive loss of nigral dopaminergic neurons. Although symptomatic therapies to substitute for the missing neurotransmitter dopamine are efficient at the early stages of the disease, the goal is to find alternative therapies which could protect dopaminergic neurons from the degenerative process. We have used two distinct gene therapy approaches to deliver the neuroprotective molecule glial cell line-derived neurotrophic factor (GDNF) in animal models of the disease: (i) an encapsulated genetically engineered cell line releasing GDNF (ex vivo gene therapy); and (ii) a lentiviral vector encoding the GDNF gene (in vivo gene therapy). Both approaches allowed protection of nigral dopaminergic neurons against lesion-induced cell death in rodent as well as monkey models of PD. Behavioral symptoms were also ameliorated in these animals. In addition, co-transplantation of embryonic dopaminergic neuronal grafts and a GDNF-releasing capsule allowed improvement of graft survival and differentiation, thereby accelerating behavioral recovery. These results should lead to clinical application in the near future.
Mots-clé
Animals
Brain Tissue Transplantation/*methods
Cells, Cultured
Diffusion Chambers, Culture/methods
Gene Therapy/instrumentation/*methods
Genetic Vectors/*therapeutic use
Glial Cell Line-Derived Neurotrophic Factor
Humans
*Nerve Growth Factors
Nerve Tissue Proteins/genetics/secretion/*therapeutic use
Parkinsonian Disorders/*genetics/physiopathology/*therapy
Substantia Nigra/pathology/physiopathology/*surgery
Pubmed
Web of science
Création de la notice
28/01/2008 9:44
Dernière modification de la notice
20/08/2019 16:27